145 related articles for article (PubMed ID: 35153806)
1. Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.
Sala L; Leonov V; Mura M; Giannetti F; Khudiakov A; Moretti A; Crotti L; Gnecchi M; Schwartz PJ
Front Physiol; 2021; 12():730127. PubMed ID: 35153806
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
[TBL] [Abstract][Full Text] [Related]
3. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
[TBL] [Abstract][Full Text] [Related]
4. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159
[TBL] [Abstract][Full Text] [Related]
6. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
Shinozawa T; Nakamura K; Shoji M; Morita M; Kimura M; Furukawa H; Ueda H; Shiramoto M; Matsuguma K; Kaji Y; Ikushima I; Yono M; Liou SY; Nagai H; Nakanishi A; Yamamoto K; Izumo S
Stem Cell Reports; 2017 Feb; 8(2):226-234. PubMed ID: 28111276
[TBL] [Abstract][Full Text] [Related]
7. Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics.
Charrez B; Charwat V; Siemons BA; Goswami I; Sakolish C; Luo YS; Finsberg H; Edwards AG; Miller EW; Rusyn I; Healy KE
Front Pharmacol; 2021; 12():684252. PubMed ID: 34421592
[TBL] [Abstract][Full Text] [Related]
8. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive assessment of proarrhythmic risks associated with isoprenaline and the dietary supplement ingredient synephrine using human induced pluripotent stem cell-derived cardiomyocytes.
Yuan X; Yu T; Zhang Z; Li S
Front Cardiovasc Med; 2024; 11():1407138. PubMed ID: 38911513
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive
Yoon SH; Lee HL; Jeong DU; Lim KM; Park SJ; Kim KS
Front Pharmacol; 2023; 14():1220796. PubMed ID: 37649890
[TBL] [Abstract][Full Text] [Related]
11. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
12. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
[TBL] [Abstract][Full Text] [Related]
13. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.
Singh AP; Tousif S; Umbarkar P; Lal H
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549293
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
[TBL] [Abstract][Full Text] [Related]
15. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
Paci M; Casini S; Bellin M; Hyttinen J; Severi S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
[TBL] [Abstract][Full Text] [Related]
16. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.
Guo L; Qian JY; Abrams R; Tang HM; Weiser T; Sanders MJ; Kolaja KL
Cell Physiol Biochem; 2011; 27(5):453-62. PubMed ID: 21691062
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxychloroquine treatment on QT interval.
Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
[TBL] [Abstract][Full Text] [Related]
18. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
Yamazaki D; Kitaguchi T; Ishimura M; Taniguchi T; Yamanishi A; Saji D; Takahashi E; Oguchi M; Moriyama Y; Maeda S; Miyamoto K; Morimura K; Ohnaka H; Tashibu H; Sekino Y; Miyamoto N; Kanda Y
J Pharmacol Sci; 2018 Apr; 136(4):249-256. PubMed ID: 29555184
[TBL] [Abstract][Full Text] [Related]
19. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
20. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
